摘要
医疗实践不仅需要拥有科学的量化研究,同时需要具有人文理念的质性研究;不仅要能够处理数据为主的自然科学问题,也要能分析主观信息为主的人文科学问题。而在以证据为基础的医学时代,治疗手段的获益-风险评估格外重视证据的客观性,忽略患者一些主观性的证据,但在临床需求未被满足的情况下,需要患者声音。本文通过分析患者声音的内涵,结合我国临床药物开发现状和FDA目前的相关实践,以及如何科学收集患者观点,对我国以患者为中心的药物开发提出展望。
Medical practice requires not only scientific quantitative research,but also qualitative research with humanistic concepts;it must be able to not only deal with data-based natural science issues,but also analyze human science issues based on subjective information.In the era of evidence-based medicine,the benefit-risk assessment of medical treatment pays special attention to the objectivity of evidence and ignores subjective evidence coming from patients.But when there are unmet clinical needs,patients’voices are needed.This article analyzes the connotation of patients’voice and the current status of clinical drug development in China,introduces practices of the US FDA on patient-focused drug development and methods to scientifically collect patient opinions,and puts forward suggestions for promoting patient-focused drug development in China.
作者
张新宇
周孟
张清
周天爱
马倩
杨劲
ZHANG Xin-yu;ZHOU Meng;ZHANG Qing;ZHOU Tian-ai;MA Qian;YANG Jin(School of International Pharmaceutical business,China Pharmaceutical University)
出处
《中国食品药品监管》
2021年第4期44-51,共8页
China Food & Drug Administration Magazine
关键词
药物开发
患者声音
临床价值
获益-风险评估
drug development
patient voice
clinical value
benefit-risk assessment
